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Outline 
 
• Anatomy of parathyroid glands and function 
of parathyroid hormone. 
• Classifications of hyperparathyroidism and 
epidemiology. 
• Clinical signs and symptoms. 
• Relationship to other disease processes. 
• Radiology, bony changes and their 
implications. 
The parathyroid glands 
• 4 of them  
• Situated behind the 
thyroid glands 
• Produce parathyroid 
hormone (PTH) 
http://www.patient.co.uk/health/Hyperparathyroidism.htm 
What does PTH do? 
• Regulates: 
• Serum calcium 
levels 
• Bone 
• Kidney 
• Intestine 
• Serum phosphate 
• Vitamin D synthesis 
Coetzee, M., Kruger, M. (2004) 
Poole, K.E.S., Reeve, J. (2005) 
Walter F., (2003) 
Hyperparathyroidism 
definition 
• An abnormal endocrine disorder 
characterised by hyperactivity of any of the 
4 parathyroid glands, with excessive 
secretion of parathyroid hormone. 
  Anderson, D. M. (2002) 
• It may be: 
• Primary 
• Secondary 
• Tertiary 
Kumar, Cotran, Robbins (2003) 
 
Epidemiology 
• Yu et al. (2009), Tayside, Scotland. 
• 2709 patients with PHPT (78% F) 
• Mean age: 
• Female – 68 
• Male – 64 
• In 2006 incidence was 6.72 / 1000 overall, greater in 
postmenopausal women. 
• “catch up” in 1970’s due to routine Ca2+ screening. 
• Previously more severe cases now less so 
• BUT incidence of SHPT increasing, due to general increase 
in kidney disease and specifically DM related nephropathy. 
 
Primary HPT 
• Aetiology 
• Single adenoma: 85% 
• Multiple adenoma: 5% 
• Hyperplasia: 10% 
• Carcinoma: <1% 
• Parathyroid gland(s) produce excess 
hormone due to the above. 
• 3rd most common endocrine disorder 
• Most asymptomatic or mildly symptomatic 
Sanders L. R. (2009) 
 
 
Secondary HPT 
• Aetiology 
• Renal insufficiency 
• Kidneys can’t filter phosphates so 
excess phosphates combine with 
circulating calcium. Low calcium 
levels detected, so more PTH 
produced to increase levels. 
• Also, failing kidneys don’t convert 
enough Vit D to its active form. 
• May also be caused by malabsorption 
 Fraser, (2009) 
Chronic Kidney Disease-Mineral and 
Bone Disorder 
• SHPT is part of a wider syndrome of CKD-M & BD. 
• Results in abnormalities of: 
• Calcium, phosphate, vitamin D & PTH 
• Vascular and / or other soft tissue 
calcifications 
• Bone turnover, mineralisation & volume. 
• Impairs quality of life and increases risk of mortality. 
• Controlled by medication but progressive. 
Smith and Smelt (2009) 
Moe et al. (2005) 
Tertiary HPT 
• Aetiology 
• Follows persistent parathyroid over 
activity and hyperplasia, usually due to 
2ry HPT. 
 
• The key is that the parathyroid gland 
loses it’s responsiveness to levels of 
circulating Ca2+ and begins relentless, 
autonomous production of PTH. 
   Fraser, (2009)  
Clinical signs and symptoms 
Renal Hypercalciuria, nephrolithiasis, nephrocalcinosis, 
polyuria/dipsia, failure. 
Neuromuscular Weakness, myalgia. 
Neurologic and 
psychiatric 
Memory loss, depression, psychoses, neuroses, 
confusion, lethargy, fatigue, paraesthesias. 
Skeletal Bone pain, osteitis fibrosa, osteopaenia/porosis, 
subperiosteal resorption. 
GI Abdominal pain, nausea, peptic ulcer, constipation, 
pancreatitis. 
Vasculature Hypertension, hypercalcaemia causes 
vasoconstriction. Arterial calcification. 
Arthralgia, synovitis, 
arthritis 
Deposition of crystals of: calcium phosphate, calcium 
pyrophosphate, urate. 
Blood Anaemia, ↑HPT, Hypercalcaemia (OR Hypo), 
Hypophosphataemia (OR Hypo). Alkaline phosphatase 
may be elevated. 
Cornea Band keratopathy, calcium phosphate precipitation.  
Distinguishing the types 
PTH Ca2+ PO4- Alkaline 
Phosphatase 
1ry 
↑ ↑ ↓ 
Normal 
2ry 
 ↑ ↓ ↑ May be elevated 
3ry ↑ ↑  ↑ ↓ ? 
Diagnosis 
• Clinical signs and symptoms 
• Could be anything 
• Radiographs 
• Bony changes 
• Soft tissue calcification 
• Female and over 40 
• Presence of associated disease processes 
• Diabetes, kidney dysfunction, gout 
• Request bloods 
 
Normal blood values 
• PTH: 10 - 65ng/l 
• Ca2+: 2.25 - 2.75 mmol/l 
• PO43-: 0.97 - 1.45 mmol/l  
• Alkaline Phosphatase: 0.5 - 2.0 microKat/l 
(Adult)  
• Child / adolescent figures higher. 
• All units are SI units. 
• Local variations may apply. 
Pagana & Pagana (2006) 
 
 
Osteopenia / porosis 
• Many factors 
• Diseases, CRPS, drugs, diet, hormone imbalances, 
age, activity, smoking, sun, vitamin D deficiency, 
femaleness, low body weight, late menarche etc. 
• Conventional radiographs have low sensitivity, 30 - 
50% bone loss required. 
• Peripheral bone-mass measurements performed 
using: 
• DXA, QCT or QUS 
• Treatment 
• Removal of parathyroid gland(s) if HPT, reversal of 
above factors if possible, bisphosphonates   
 

Radiology 
• Generalised osteopaenia 
• Cortical thinning 
• Fractures 
• Subperiosteal resorption (hands and feet; 
phalangeal tufts, erosions) 
• Subligamentous and tendinous resorption 
(plantar fascia and TA)  
Lenchik & Sartoris (1998). 
Radiology 
• Sclerosis (spine, 2ry HPT) 
• Brown tumours 
• Chondrocalcinosis 
• ST and vascular calcification (2ry 
HPT) 
 
• It’s the bony changes due to the 
disease process that are seen 
radiologically that are the main direct 
challenge in podiatric surgery. 
 
Radiology 
By kind permission of  
Mr. A Waddington  
Fractures / stress fractures 
• Insufficiency / pathological fracture 
• Fracture due to normal loading of 
abnormal bone. 
• The foot is a common place for stress 
fractures: 
• Calcaneus, metatarsals, navicular, other 
tarsals. 
• Demineralisation of bone in HPT make such 
patients more susceptible to fractures / 
stress fractures in the foot, . 
Fishco & Stiles (1999) 
Healing calcaneal stress fracture 
subsequent to SHPT.  
Fishco & Stiles (1999) 
Fixation difficulties 
• Osteoporosis per sé is not a barrier to 
fracture healing, although age might be. 
• BUT Problems include: 
• Thin bone cortices reduce holding power 
of screws. 
•  core diameter, pitch of thread. 
• Risk of further fracture. 
• Instability of fixation materials. 
• Thus, more screws & plates needed 
which may impair vascularity & 
healing. 
• May alter choice of procedure.  
 
Strømsøe (2003) 
Fixation difficulties 
• Reduced holding power of fixations in 
osteoporotic bone results in 10 – 
25% failure rate. 
• Fixation devices that share loading 
with host bone that minimise stress 
on the device and bone. 
• Screws should be placed into cortical 
bone but parallel to trabeculae. 
• Consider use of allografts or fillers 
like polymethylmethacrylate. 
 Cornell (2003) 
Fixation difficulties 
Weil et al., (2008) 
QuickTime™ and a
TIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and a
TIFF (LZW) decompressor
are needed to see this picture.
Osteitis Fibrosis Cystica 
• AKA: Brown Tumours or Von 
Recklinghausens disease of bone. 
• Benign, cystic bone lesions due to 
osteoclastic resorption, filled with 
vascularised fibrotic tissue. 
• Occurs in: 3% of PHPT patients and 1.5% of 
SHPT cases. 
• Tend to regress following 
parathyroidectomy. 
• Occur in the appendicular skeleton, including 
the foot, reports of tumours in the calcaneus 
and metatarsals.  
Yazgan (2008) 
CT of Brown tumour in Right 3rd metatarsal. 
Yazgan (2008) 
Gout 
• Higher incidence of gout in patients with PHPT. 
• Partly caused by reduced renal clearance of 
urate. 
• Excision of parathyroid gland may lead to 
significant falls in serum urate levels. 
Broulik et al. (1987) 
Nirenberg and Carroll (2007) 
T2 weighted MRI, showing cystic changes of 
ankle and STJ due to gout subsequent to SHPT. 
Nirenberg & Carroll (2007) 
Diabetes mellitus 
• Prevalence of DM in HPT is 8% 
• Prevalence of HPT in DM is 1% 
• Both 3X higher than expected in general 
population. 
• Patients with both tend to be: 
• Female and over 40 years old  
• Some evidence that parathyroidectomy improves 
concurrent DM. 
• HPT presents 1st = 20% 
• DM presents 1st = 40% 
• HPT & DM present together = 40%  
 
Taylor and Khaleeli, (2001). 
Quin and Gumpert, (1997). 
Hypothesis explaining how diabetes might arise in primary hyperparathyroidism 
Taylor and Khaleeli (2001) 
Other considerations 
• Renal pathology of HPT precludes 
administration of NSAIDs 
postoperatively. 
• Sequelae of HPT include constipation, 
thus administration of co-codamol 
precluded? 
• Vascular calcification increases risk of 
intra and post operative bleeding. 
 
Summary 
• Not a condition encountered every day in podiatric 
surgery 
• But in patients where it presents it may have direct 
and indirect implications. 
• Reduced bone density due to leaching of Ca2+ / 
renal osteodystrophy. 
• Fractures / stress fractures 
• Problems with fixation 
• Tendon rupture 
• Take bloods from patients with evidence of 
osteopaenia on X-ray and who fit profile of 
symptoms or links with other disease processes? 
 
Summary 
• Also, links to: diabetes, gout, brown 
tumours, all of which may manifest in the 
foot. 
• Fall risk post operatively: 
• Damage to surgery site / fracture. 
• Hip fracture 
• Plus, patients may have associated 
concurrent conditions which may reduce 
their ASA status and make them a greater 
surgical risk. 
• Delay pod surgery until after 
parathyroidectomy or controlled with 
medication? 
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